Key facts
- It has raised $250.0M; the latest was Early Stage VC ($150.0M) in Mar 2026.
- Notable investors include Qiming Venture Partners, GL Ventures, Lenovo Capital and Incubator Group, CDH Investments, 5Y Capital — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Syneron
- ·The full record, as it builds
Funding rounds
No funding rounds for Syneron are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Syneron
Developer of peptide therapeutics designed to accelerate the discovery and development of novel drug candidates. The company offers peptide design capabilities, high-throughput screening systems, and predictive property algorithms, enabling pharmaceutical developers to streamline early-stage research and improve drug development efficiency.
- Sector
- Healthcare
- HQ
- Guangzhou, China
- Founded
- 2022
- Website
- syneronbio.com/
- Ownership
- Privately Held (backing)
Syneron doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Syneron shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Syneron in its N-PORT filings yet. We sweep new filings monthly.